GSID - ETF AI Analysis
Top Page
Goldman Sachs MarketBeta International Equity ETF (GSID)
Rating:66Neutral
Price Target:―
Positive Factors
Broad International Diversification
The fund spreads its investments across many countries, including Japan, the UK, and several European and Asia-Pacific markets, which helps reduce reliance on any single economy.
Balanced Sector Mix
Holdings are spread across financials, industrials, health care, technology, and other sectors, helping to cushion the impact if one industry runs into trouble.
Competitive Expense Ratio
The fund’s relatively low expense ratio means less of your return is lost to fees compared with many actively managed international funds.
Negative Factors
Heavy Financials Exposure
A large allocation to financial companies makes the fund more sensitive to banking and interest-rate risks.
Concentration in a Few Countries
Significant weight in markets like Japan and the UK means the fund’s performance can be heavily influenced by economic or political developments in those countries.
Mixed Performance Among Top Holdings
While some leading positions have shown strong gains, others have been weak or lagging, which can create uneven contributions to overall returns.
GSID vs. SPDR S&P 500 ETF (SPY)
AUM1.00B
RegionDeveloped Markets
Expense Ratio0.20%
Beta0.75
IssuerGoldman Sachs
Inception DateMay 12, 2020
Dividend Yield2.61%
Asset ClassEquity
Index TrackedSolactive GBS Developed Markets ex North America Large & Mid Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume182,848
30 Day Avg. Volume53,573
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
80.04Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering890
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSID Summary
The Goldman Sachs MarketBeta International Equity ETF (GSID) is an exchange-traded fund that tracks the Solactive GBS Developed Markets ex North America Large & Mid Cap Index. It invests in many large and mid-sized companies outside the U.S., with big exposure to countries like Japan, the UK, and France. Well-known holdings include Toyota Motor, Nestlé, and AstraZeneca. Someone might invest in GSID to diversify beyond the U.S. and gain broad international stock market exposure in a single fund. A key risk is that international stock prices can go up and down significantly with global market and currency moves.
How much will it cost me?The Goldman Sachs MarketBeta International Equity ETF (GSID) has an expense ratio of 0.20%, which means you’ll pay $2 per year for every $1,000 invested. This is lower than average for ETFs because it is passively managed, tracking an index rather than relying on active management strategies.
What would affect this ETF?Positive drivers for GSID could include strong growth in developed markets outside North America, particularly in sectors like financials and industrials, which make up a significant portion of the ETF's holdings. However, negative factors such as rising interest rates or economic slowdowns in these regions could impact corporate earnings and investor sentiment, especially for top holdings like ASML and Nestlé. Additionally, regulatory changes in key countries or global trade tensions could create uncertainty for the ETF's performance.
GSID Top 10 Holdings
GSID leans heavily into non-U.S. blue chips, with Europe and Japan doing most of the heavy lifting. ASML has been a star, rising strongly and giving the fund a powerful tech engine, while Toyota and Mitsubishi UFJ add steady support from Japan’s industrial and financial hubs. The real backbone, though, is health care: Roche, Novartis, and AstraZeneca have all been climbing, turning pharma into a key performance driver. Nestlé and Shell are more steady than exciting, and Siemens has been a bit mixed lately, occasionally tapping the brakes on returns.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.49% | $24.92M | €454.94B | 77.87% | 76 Outperform | |
| Novartis AG | 1.39% | $13.91M | CHF227.43B | 23.72% | 80 Outperform | |
| Roche Holding AG | 1.36% | $13.65M | $317.10B | 14.86% | 73 Outperform | |
| AstraZeneca | 1.36% | $13.62M | $294.03B | 21.58% | 80 Outperform | |
| HSBC Holdings | 1.30% | $13.05M | £207.68B | 34.99% | 80 Outperform | |
| Nestlé SA | 1.25% | $12.51M | CHF197.20B | -1.46% | 71 Outperform | |
| Shell (UK) | 1.23% | $12.36M | £194.90B | 26.29% | 73 Outperform | |
| Toyota Motor | 1.05% | $10.51M | ¥44.37T | 17.98% | 80 Outperform | |
| Commonwealth Bank of Australia | 0.98% | $9.83M | AU$296.06B | 23.36% | 64 Neutral | |
| SAP SE | 0.92% | $9.25M | €183.81B | -34.51% | 66 Neutral |
GSID Technical Analysis
Negative
―
Price Trends
73.02
Negative
70.38
Negative
67.36
Positive
Market Momentum
-0.92
Positive
37.01
Neutral
34.31
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSID, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 73.07, equal to the 50-day MA of 73.02, and equal to the 200-day MA of 67.36, indicating a neutral trend. The MACD of -0.92 indicates Positive momentum. The RSI at 37.01 is Neutral, neither overbought nor oversold. The STOCH value of 34.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GSID.
GSID Peer Comparison
Comparison Results
Performance Comparison
GSID
Goldman Sachs MarketBeta International Equity ETF
70.02
11.10
18.84%
JIRE
JPMorgan International Research Enhanced Equity ETF
―
―
―
DBEF
Xtrackers MSCI EAFE Hedged Equity ETF
―
―
―
FENI
Fidelity Enhanced International ETF
―
―
―
BBIN
JPMorgan BetaBuilders International Equity ETF
―
―
―
EFAV
iShares MSCI EAFE Min Vol Factor ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents